Nab-TPC vs GP Combined With Camrelizumab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma

NCT06669611 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

242

Enrollment

OTHER

Sponsor class

Conditions

Nasopharyngeal Cancinoma (NPC)

Interventions

DRUG: Camrelizumab combined GP chemotherapy
DRUG: Camrelizumab combined TPC chemotherapy

Sponsor

Sun Yat-sen University